Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study

Banerjee S.; Oza A. M.; Birrer M. J.; Hamilton E. P.; Hasan J.; Leary A.; Moore K. N.; Mackowiak-Matejczyk B.; Pikiel J.; Ray-Coquard I.; Trask P.; Lin K.; Schuth E.; Vaze A.; Choi Y.; Marsters J. C.; Maslyar D. J.; Lemahieu V.; Wang Y.; Humke E. W.; Liu J. F.

首页> 外文期刊>Annals of oncology: official journal of the European Society for Medical Oncology >Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study

【24h】

Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study

机译：抗NaPi2B抗体 - 药物缀合物Lifastuzumab Vedotin（DNIB0600A）与铂抗脂质糖尿病患者在随机的，开放标签，II期研究中的患者患者中相比

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: Lifastuzumab vedotin (LIFA) is a humanized anti-NaPi2b monoclonal antibody conjugated to a potent antimitotic agent, monomethyl auristatin E, which inhibits cell division by blocking the polymerization of tubulin. This study is the first to compare an antibody-drug conjugate (ADC) to standard-of-care in ovarian cancer (OC) patients.

机译：背景：Lifastuzumab Vedotin（LIFA）是与有效的抗杀氧剂，单甲基Auristatin E缀合的人源化抗NaPi2B单克隆抗体，其通过阻断管蛋白的聚合来抑制细胞分裂。本研究是首先将抗体 - 药物缀合物（ADC）与卵巢癌（OC）患者进行标准进行比较。

著录项

来源
《Annals of oncology: official journal of the European Society for Medical Oncology》 |2018年第4期|共7页
作者
Banerjee S.; Oza A. M.; Birrer M. J.; Hamilton E. P.; Hasan J.; Leary A.; Moore K. N.; Mackowiak-Matejczyk B.; Pikiel J.; Ray-Coquard I.; Trask P.; Lin K.; Schuth E.; Vaze A.; Choi Y.; Marsters J. C.; Maslyar D. J.; Lemahieu V.; Wang Y.; Humke E. W.; Liu J. F.;
展开▼
作者单位

Royal Marsden NHS Fdn Trust London England;

Princess Margaret Hosp Toronto ON Canada;

Massachusetts Gen Hosp Boston MA 02114 USA;

Sarah Cannon Res Inst Nashville TN USA;

Christie Hosp Manchester Lancs England;

Gustave Roussy Canc Ctr Paris France;

Univ Oklahoma Hlth Sci Ctr Oklahoma City OK USA;

Bialystok Oncol Ctr Bialystok Poland;

Reg Ctr Oncol Gdansk Poland;

Ctr Leon Berard Ctr Reg Lutte Canc Rhone Alpes Lyon France;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Harvard Med Sch Boston MA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
NaPi2b; antibody-drug conjugate; platinum-resistant; ovarian cancer; clinical trial; lifastuzumab;

机译：NAPI2B;抗体 - 药物缀合物;抗铂;卵巢癌;临床试验;Lifastuzumab;

相似文献

外文文献
中文文献
专利

1. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study [J] . Banerjee S., Oza A. M., Birrer M. J., Annals of oncology: official journal of the European Society for Medical Oncology . 2018,第4期

机译：抗NaPi2B抗体 - 药物缀合物Lifastuzumab Vedotin（DNIB0600A）与铂抗脂质糖尿病患者在随机的，开放标签，II期研究中的患者患者中相比
2. Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer [J] . Gerber David E., Infante Jeffrey R., Gordon Michael S., Clinical cancer research: an official journal of the American Association for Cancer Research . 2020,第2期

机译：抗NaPi2B抗体 - 药物缀合物Lifastuzumab Vedotin DNIB0600A的IA类研究，非小细胞肺癌和抗铂卵巢癌患者
3. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer [J] . ColomboN., KutarskaE., DimopoulosM., Journal of Clinical Oncology . 2012,第31期

机译：随机，开放标签的，III期研究，比较了铂难治性或耐药性复发性上皮性卵巢癌，原发性输卵管癌或原发性腹膜癌患者中帕特匹龙（EPO906）与聚乙二醇化脂质体阿霉素的比较
4. COMPLEMENT ACTIVATION BY PEGYLATED LIPOSOMAL DOXORUBICIN (DOXIL~R) IN CANCER PATIENTS: ASSOCIATION WITH HYPERSENSITIVITY REACTIONS [C] . A. Chanan-Khan, J. Szebeni, L. Leibes, International symposium on controlled release of bioactive materials;Consumer diversified products conference . 2001

机译：聚脂脂质体阿霉素（DOXIL〜R）在癌症患者中的补体激活：与超敏反应的关联
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer [O] . Bradley J. Monk, Thomas J. Herzog, George Wang, 2020

机译：先前在复发性卵巢癌中使用聚乙二醇化脂质体阿霉素（PLD）治疗的数据：来自3期随机开放标签研究的事后数据分析比较了复发性卵巢癌患者中的Trabectedin和PLD与单独使用PLD
7. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer [O] . William P. McGuire, Richard T. Penson, Martin Gore, 2018

机译：PDGFRα抗体的随机期II研究奥拉妥拿胶加脂质体DOXORUBICIN与脂质体多柔比蛋白单独患者铂 - 难治性或铂抗性晚期卵巢癌的患者

Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study

摘要

著录项

相似文献

相关主题

期刊订阅